Welcome to our dedicated page for Inspira Tech news (Ticker: IINNW), a resource for investors and traders seeking the latest updates and insights on Inspira Tech stock.
Inspira Technologies (IINNW) is a pioneering medical device company developing non-invasive respiratory support solutions. This page serves as the definitive source for all official company announcements, financial disclosures, and innovation updates.
Investors and industry professionals will find timely updates on regulatory milestones, clinical trial progress, and strategic partnerships. Our curated news collection provides transparent access to earnings reports, product launch details, and market expansion initiatives.
Key areas of coverage include advancements in the INSPIRA ART system, HYLA blood sensor developments, and distribution agreements with global healthcare providers. Content is organized to help stakeholders track technological breakthroughs shaping critical care.
Bookmark this page for direct access to Inspira Technologies' latest press releases. Regular updates ensure awareness of developments in next-generation respiratory support technologies.
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN)(NASDAQ:IINNW) is set to present at the 2023 Planet MicroCap Showcase in Las Vegas on April 26, 2023, at 14:30 CST. Joe Hayon, President and Co-Founder, will lead the presentation. Interested parties can access the live presentation via the provided webcast link. Registration for the event is necessary, which can be done here. Additionally, one-on-one virtual meetings can be scheduled with Joe throughout May by using this link. Inspira Technologies focuses on innovative respiratory treatments, particularly its Augmented Respiration Technology, aimed at improving patient outcomes while minimizing the use of invasive mechanical ventilation.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) reported its financial results for the year ended December 31, 2022. The company has $13.9 million in cash, a decrease from $23.7 million in 2021, with shareholders' equity falling to $12.8 million from $20.3 million. R&D expenses increased to $8 million from $3.9 million in the previous year. The net loss showed improvement at $10.3 million compared to $17 million in 2021. The company plans to submit its ALICE device for FDA approval in H2 2023 and is conducting clinical studies for its HYLA blood sensor. Inspira continues to advance its INSPIRA ART system aimed at non-invasive respiratory treatment.
FAQ
What is the current stock price of Inspira Tech (IINNW)?
